<br>        Inclusion Criteria:<br><br>          -  Signed an informed consent document indicating they understand the purpose of and<br>             procedures required for the study and are willing to participate in the study<br><br>          -  Body mass index (BMI) between 18 and 30 kilogram (kg)/meter square ([m]^2)<br>             (inclusive), and body weight not less than 50 kilogram (kg)<br><br>          -  Women using oral contraceptives must agree to use an additional birth control method<br>             during the study and for 1 month after receiving the last dose of study drug or until<br>             after the next menstrual period<br><br>          -  A woman of child-bearing potential, must have a negative serum beta-human chorionic<br>             gonadotropin (hCG) pregnancy test at Screening and a negative urine pregnancy test on<br>             Day -1 of the first treatment period<br><br>          -  A man, must agree to use an adequate contraception method as deemed appropriate by the<br>             investigator (example, vasectomy, double-barrier, partner using effective<br>             contraception) and to not donate sperm during the study and for 3 months after<br>             receiving the last dose of study drug<br><br>        Exclusion Criteria:<br><br>          -  Participant has a current diagnosis of psychotic disorder or major depressive disorder<br>             (MDD) with psychosis, bipolar or related disorders, intellectual disability,<br>             borderline personality disorder, or antisocial personality disorder<br><br>          -  Clinically significant medical illness including (but not limited to) cardiac<br>             arrhythmias or other cardiac disease, hematologic disease, lipid abnormalities,<br>             significant pulmonary disease, including bronchospastic respiratory disease, diabetes<br>             mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric<br>             disease, infection, gastrointestinal disease, hypertension, vascular disorders, sleep<br>             apnea, myasthenia gravis, or any other illness that the investigator considers should<br>             exclude the participant or that could interfere with the interpretation of the study<br>             results<br><br>          -  History of additional risk factors for torsade de pointes or the presence of a family<br>             history of Short QT Syndrome, Long QT Syndrome, sudden unexplained death at a young<br>             age (less than/equal to 40 years), drowning or sudden infant death syndrome in a first<br>             degree relative (that is, biological parent, sibling, or child)<br><br>          -  Clinically significant abnormal values for hematology, clinical chemistry or<br>             urinalysis at Screening or at admission to the study center for the first treatment<br>             period as deemed appropriate by the investigator. Electrolytes (potassium, magnesium,<br>             calcium) should be within the reference range of the laboratory<br><br>          -  Clinically significant abnormal physical examination, vital signs, or 12 lead<br>             electrocardiogram (ECG) at Screening or at admission to the study center for the first<br>             treatment period as deemed appropriate by the investigator<br>